No Priors Ep. 121 | With Chai Discovery Co-Founders Jack Dent and Joshua Meier

In this episode of No Priors, the hosts interview Josh Meyer and Jack Dent, co-founders of Chai Discovery, about their new Chai-2 zero-shot antibody discovery platform. They discuss the platform's capabilities, which include designing antibodies that bind to specified targets with significantly higher success rates than traditional methods. The conversation covers the underlying technology, the impact on drug discovery, and the future of biotech, highlighting the potential for AI to transform biology into an engineering discipline. Meyer and Dent also share insights into company building, hiring strategies, and the importance of platform investment.